CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...
“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...
Researchers at Washington University School of Medicine in St. Louis have conducted a longitudinal study on an individual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback